Pharmacological IRS1/2 Inhibition Reduces Cell Viability in BCR-ABL1 Positive Cells

被引：0
|
作者：
Scopim-Ribeiro, Renata [1 ]
Machado-Neto, Joao Agostinho [1 ]
Campos, Paula de Melo [2 ]
Santos Duarte, Adriana da Silva [2 ]
Scheucher, Priscila Santos [1 ]
Goes, Amelia [1 ]
Olalla Saad, Sara Teresinha [2 ]
Simoes, Belinda Pinto [1 ]
Rego, Eduardo Magalhaes [1 ]
Traina, Fabiola [1 ]
机构：
[1] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Internal Med, BR-14049 Ribeirao Preto, Brazil
[2] Univ Estadual Campinas, Inst Nacl Ciencia & Tecnol Sangue, Hematol & Hemotherapy Ctr, Campinas, SP, Brazil
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Pharmacological IRS1/2 Inhibition Induces Apoptosis in BCR-ABL1T3151 mutant Cells
    Scopim-Ribeiro, Renata
    Machado-Neto, Joao Agostinho
    Eide, Christopher A.
    Campos, Paula de Melo
    Scheucher, Priscila Santos
    Saad, Sara Teresinha Olalla
    Rego, Eduardo Magalhaes
    Tognon, Cristina E.
    Druker, Brian J.
    Traina, Fabiola
    BLOOD, 2016, 128 (22)
  • [2] PARP Inhibition Sensitize BCR-ABL1 Positive Cell
    Hiroki, Haruka
    Ishii, Yuko
    Piao, Jinhua
    Morio, Tomohiro
    Takagi, Masatoshi
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S12 - S12
  • [3] PARP Inhibition Sensitize BCR-ABL1 Positive Cel
    Hiroki, Haruka
    Takagi, Masatoshi
    Ishi, Yuko
    Piao, Jinhua
    Morio, Tomohiro
    BLOOD, 2019, 134
  • [4] THE STEMNESS INHIBITOR, BBI608, REDUCES THE SELF-RENEWAL OF BCR-ABL1 POSITIVE LEUKEMIA CELLS
    Tauchi, T.
    Okabe, S.
    Katagiri, S.
    Ohyashiki, K.
    HAEMATOLOGICA, 2015, 100 : 28 - 28
  • [5] Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
    Maletzke, Saskia
    Salimi, Azam
    Vieri, Margherita
    Schroeder, Kema Marlen
    Schemionek, Mirle
    Masouleh, Behzad Kharabi
    Brummendorf, Tim H.
    Koschmieder, Steffen
    Appelmann, Iris
    PLOS ONE, 2022, 17 (10):
  • [6] Inhibition Of PI3K/mTOR Overcomes Nilotinib Resistance In BCR-ABL1 Positive Leukemia Cells
    Ding, Jie
    Romani, Julia
    Zaborski, Margarete
    MacLeod, Roderick A. F.
    Nagel, Stefan
    Drexler, Hans G.
    Quentmeier, Hilmar
    BLOOD, 2013, 122 (21)
  • [7] Combination of BCR-ABL1 Tyrosine Kinase Inhibitors with a Small Molecule LIM kinase1/2 Inhibitor in BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
    Braun, Thorsten
    Berrou, Jeannig
    Prudent, Renaud
    Djamai, Hanane
    Dupont, Melanie
    Kaci, Anna
    Adiceam, Emilie
    Paublant, Fabrice
    Baruchel, Andre
    Ghysdael, Jacques
    Gardin, Claude
    Dombret, Herve
    BLOOD, 2018, 132
  • [8] BCR-ABL1 positive lymphoblastic lymphoma - should it be treated like a B-lymphoblastic leukemia with t(9;22);BCR-ABL1?
    Takahashi, Taro
    Ichikawa, Satoshi
    Ichinohasama, Ryo
    Harigae, Hideo
    LEUKEMIA & LYMPHOMA, 2020, 61 (05) : 1265 - 1267
  • [9] INHIBITION OF PI3K/MTOR OVERCOMES NILOTINIB RESISTANCE IN BCR-ABL1 POSITIVE LEUKEMIA CELLS
    Ding, J.
    Romani, J.
    Zaborski, M.
    Nagel, S.
    Drexler, H.
    Quentmeier, H.
    HAEMATOLOGICA, 2013, 98 : 402 - 403
  • [10] Arsenic Trioxide Suppresses Growth of BCR-ABL1 Positive Cells with "Gatekeeper" or Compound Mutation
    Mian, Afsar Ali
    Raees, Hadiqa
    Ahmad, Sujjawal
    Ottmann, Oliver
    Lalani, El-Nasir M. A.
    BLOOD, 2021, 138
12345